NasdaqGS:AMRXPharmaceuticals
KeifeRx LRRK2 Parkinson’s Collaboration Might Change The Case For Investing In Amneal Pharmaceuticals (AMRX)
In early January 2026, KeifeRx announced a research collaboration and option agreement with Amneal Pharmaceuticals to support pre-IND development of KFRX06, a brain-penetrant LRRK2 inhibitor candidate for Parkinson’s disease.
This agreement adds an early-stage neuroscience asset to Amneal’s pipeline and leverages its Parkinson’s development and manufacturing capabilities in a specialized genetic target area.
We’ll now examine how adding an LRRK2-targeted Parkinson’s candidate through KeifeRx...